Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Biostatistics for clinician researchers 2: Survival and K-M analysis

ecancer Kathmandu 2023 Research Methods Workshop

28 - 29 Oct 2023

Published: 29 Oct 2023

Views: 183

Rating:

Save

Dr Martin Stockler - Sidney University, Australia

Dr Martin Stockler speaks at the ecancer Kathmandu 2023 Research Methods Workshop, which was held in Nepal, on 28th and 29th of October 2023.

Related Videos

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

The Vietnam National Cancer Institute’s efforts in improving cancer care in Vietnam

Dr Thanh Huong Tran Thi - Director, Vietnam National Cancer Institute

The Vietnam National Cancer Institute’s efforts in improving cancer care in Vietnam ( Dr Thanh Huong Tran Thi - Director, Vietnam National Cancer Institute )

Time toxicity: the burden on cancer patients

Dr Arjun Gupta - University of Minnesota, Minneapolis, USA

Time toxicity: the burden on cancer patients ( Dr Arjun Gupta - University of Minnesota, Minneapolis, USA )

The time toxicity of cancer care

Dr Arjun Gupta - University of Minnesota, Minneapolis, USA

The time toxicity of cancer care ( Dr Arjun Gupta - University of Minnesota, Minneapolis, USA )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Choosing Wisely in medical oncology

Dr Omar AbdiHamid - Garissa Cancer Center, Garissa, Kenya

Choosing Wisely in medical oncology ( Dr Omar AbdiHamid - Garissa Cancer Center, Garissa, Kenya )

More from ecancer